体外间充质基质细胞疗法治疗透析依赖的急性肾损伤
本研究为一项多中心、随机、双盲、假对照的Ib/IIa期临床试验,计划纳入最多32例接受连续性肾脏替代治疗(CRRT)的急性肾损伤(AKI)患者,评估体外间充质基质细胞产品SBI-101的安全性和耐受性。受试者随机接受假对照、低剂量(250×10^6个MSCs)或高剂量(750×10^6个MSCs)SBI-101治疗,主要观察剂量依赖性安全性、肾脏疗效及探索性生物标志物。
要点
- SBI-101将异体人间充质基质细胞接种于中空纤维血滤器,体外给药以克服移植药代动力学屏障。
- 研究设计为随机双盲假对照,目标入组24例可评估的CRRT依赖AKI患者。
- 主要目的是评估SBI-101在AKI患者中的安全性和耐受性。
核心结论
- 这项首次人体临床试验将评估SBI-101在需要CRRT的AKI患者中的安全性和耐受性。
研究设计与样本
- 前瞻性、多中心、随机、双盲、假对照的Ib/IIa期临床研究。
- 计划入组最多32例受试者,以提供24例符合方案人群。
- 受试者为临床诊断AKI并接受CRRT的患者,随机接受假对照、低剂量(250×10^6 MSCs)或高剂量(750×10^6 MSCs)SBI-101治疗。
主要发现
- 研究将测量剂量依赖性安全性、肾脏疗效和探索性生物标志物,以表征SBI-101的药代动力学和药效学。
关键数值与推荐
- SBI-101包含异体人间充质基质细胞,接种于中空纤维血滤器,体外给药。
- 低剂量为250×10^6 MSCs,高剂量为750×10^6 MSCs,对照为0 MSCs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The pathophysiology of acute kidney injury (AKI) involves damage to renal epithelial cells, podocytes, and vascular beds that manifests into a deranged, self-perpetuating immune response and peripheral organ dysfunction. Such an injury pattern requires a multifaceted therapeutic to alter the wound healing response systemically. Mesenchymal stromal cells (MSCs) are a unique source of secreted factors that can modulate an inflammatory response to acute organ injury and enhance the repair of injured tissue at the parenchymal and endothelial levels. This phase Ib/IIa clinical trial evaluates SBI-101, a combination product that administers MSCs extracorporeally to overcome pharmacokinetic barriers of MSC transplantation. SBI-101 contains allogeneic human MSCs inoculated into a hollow-fiber hemofilter for the treatment of patients with severe AKI who are receiving continuous renal replacement therapy (CRRT). SBI-101 therapy is designed to reprogram the molecular and cellular components of blood in patients with severe organ injury. METHODS: This study is a prospective, multicenter, randomized, double-blind, sham-controlled, study of subjects with a clinical diagnosis of AKI who are receiving CRRT. Up to 32 subjects may be enrolled to provide 24 evaluable subjects (as a per protocol population). Subjects will receive CRRT in tandem with a sham control (0 MSCs), or the low- (250 × 106 MSCs) or high-dose (750 × 106 MSCs) SBI-101 therapeutic. RESULTS: The study will measure dose-dependent safety, renal efficacy, and exploratory biomarkers to characterize the pharmacokinetics and pharmacodynamics of SBI-101 in treated subjects. CONCLUSION: This first-in-human clinical trial will evaluate the safety and tolerability of SBI-101 in patients with AKI who require CRRT.
引用
- Miller BLK, Garg P, Bronstein B, et al. Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury. Kidney Int Rep. 2018. PMID: 30197978. doi:10.1016/j.ekir.2018.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。